Sirtex Medical

What Sirtex Medical does

Sirtex Medical is a global interventional oncology company specializing in targeted radiation therapy for liver cancer. The company's core technology is SIR-Spheres Yttrium-90 (Y-90) resin microspheres used in Selective Internal Radiation Therapy (SIRT), which delivers high-dose beta radiation directly to liver tumors via catheter-based administration into the hepatic artery while sparing healthy liver tissue. The microspheres (20-60 microns in diameter) are deployed in a two-step procedure involving pre-treatment mapping followed by therapeutic dose administration, enabling personalized dosimetry via the partition model approach. Supporting products include the SIROS Delivery System (European launch 2024), the FLEXdose SELECT program (3mL vials for patient-specific dosing launched August 2024), the LAVA Liquid Embolic System, EmboCept S DSM embolic agent, and INSYTE with SurePlan LiverY90 treatment planning software (partnered with MIM Software). The company holds dual FDA approvals (HCC in July 2025, mCRC previously), EU MDR certification, and expanded CE Mark indication covering primary and secondary liver metastases.

Sirtex generates revenue primarily through direct sales of its prescription medical device to hospitals and cancer centers, with pricing conducted on a quote-based model through account-based online ordering platforms. The go-to-market relies on specialized enterprise field sales teams targeting interventional radiologists, nuclear medicine physicians, and oncology teams in the U.S., Europe, Middle East, Africa, and key Asian markets, supplemented by international distributors in countries without direct registration (Hong Kong, Israel, Malaysia, New Zealand, Taiwan, Thailand). The company operates four manufacturing facilities (U.S., Australia, Germany, Singapore) and serves 1,300+ medical centers across 50+ countries, with 100,000+ cumulative patient doses delivered since 2002. Reimbursement approvals have been secured with NHS England, French national health insurance, and Discovery Health (South Africa).

The company is listed on the Australian Securities Exchange (ASX: SRX) under legal name Sirtex Medical Pty Ltd, with US operations headquartered in Woburn, MA, and European operations based in Bonn, Germany. Sirtex is majority-owned by China Grand Pharmaceutical and Healthcare Holdings Limited (CGP), a Hong Kong-listed conglomerate with approximately $1.8-2.1 billion USD market capitalization, following acquisition by CGP and CDH Investments. The current CEO is Matt Schmidt, who joined in February 2023 from Abbott Vascular. Sirtex also maintains a strategic minority stake (~8.8%) in OncoSec Medical (NASDAQ: ONCS), an intratumoral cancer immunotherapy company, acquired jointly with CGP for $30 million in February 2020.

Name

Sirtex Medical

Legal name

Sirtex Medical Pty Ltd

Website

https://sirtex.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

251–500 employees

Short description

Sirtex Medical is a global interventional oncology company that develops and commercializes SIR-Spheres Y-90 resin microspheres for Selective Internal Radiation Therapy (SIRT) to treat inoperable liver cancers, serving interventional radiologists and oncology teams at 1,300+ medical centers across 50+ countries.

Ownership category

akta.pro rank

Product category

Interventional Oncology / Radioembolization Medical Devices

NAICS

Irradiation Apparatus Manufacturing (334517), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

Keywords

• Interventional oncology devices
• Radioembolization therapy
• Liver cancer treatment
• Y-90 microspheres
• Embolization systems

Headquarters

HQ city

Woburn

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SIR-Spheres Y-90 Resin Microspheres Device Sales: Sirtex generates revenue primarily from the sale of its SIR-Spheres Y-90 resin microspheres as a prescription medical device. The product is sold directly to hospitals and medical centers globally, with orders placed through online ordering platforms. The company has manufacturing facilities in the U.S., Australia, Germany, and Singapore to serve global demand.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Sirtex manufactures and sells SIR-Spheres Y-90 resin microspheres, a prescription medical device used in Selective Internal Radiation Therapy (SIRT) to deliver targeted beta-radiation directly to inoperable liver tumors in patients with hepatocellular carcinoma (HCC), metastatic colorectal cancer (mCRC), intrahepatic cholangiocarcinoma (iCCA), and neuroendocrine tumor metastases. The product portfolio also includes delivery systems (SIROS, FLEXdose SELECT), embolic agents (LAVA, EmboCept S DSM 50 µm), and dosimetry planning software (INSYTE with SurePlan LiverY90), sold to hospitals and cancer centers globally.

Product overview

Sirtex Medical is a global healthcare company specializing in interventional oncology and embolization solutions for liver cancer treatment. The company's core product is SIR-Spheres Y-90 Resin Microspheres, a targeted radiation therapy using radioactive yttrium-90 microspheres delivered via selective internal radiation therapy (SIRT). Supporting products include the SIROS Delivery System for controlled administration of the microspheres, the LAVA Liquid Embolic System for vascular embolization, and EmboCept S DSM 50 μm for embolic procedures. The portfolio also includes planning tools like INSYTE with SurePlan LiverY90 for dosimetry calculations and the FLEXdose SELECT Delivery Program for more selective treatment targeting. Together, these products provide a comprehensive suite of minimally invasive, liver-directed cancer therapies.

Differentiator

Problem solved

Functional benefit

Brands

• SIR-Spheres: Y-90 resin microspheres for selective internal radiation therapy (SIRT) used in treatment of liver cancer.
• SIROS
• LAVA
• EmboCept S DSM 50 um
• FLEXdose SELECT

Products and services

• SIR-Spheres Y-90 Resin Microspheres Targeted radiation therapy using radioactive Yttrium-90 resin microspheres (20-60 microns) for Selective Internal Radiation Therapy (SIRT) of liver tumors. FDA-approved for unresectable hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC), and CE Mark approved for primary and secondary liver metastases including intrahepatic cholangiocarcinoma (iCCA) and neuroendocrine tumor metastases. Sold as a prescription medical device to hospitals and cancer centers.
• SIROS Delivery System Intuitive, visual, and adaptable delivery device for administering SIR-Spheres Y-90 resin microspheres to liver cancer patients, with controlled administration designed to provide physician confidence in Y-90 delivery. EU MDR certified for European launch.
• LAVA Liquid Embolic System Liquid embolic system used in interventional radiology procedures for vascular occlusion and embolization treatments.
• EmboCept S DSM 50 µm 50 micrometer embolic product for use in embolization procedures, available in European markets.
• INSYTE with SurePlan LiverY90 Treatment planning and dosimetry tool combining Sirtex's INSYTE delivery system with MIM Software's SurePlan LiverY90 dosimetry software. Allows physicians to calculate the dose delivered by microspheres and incorporates CT, PET, SPECT, and MRI scans simultaneously for informed treatment decisions in hepatic tumor therapy.
• SIR-Spheres FLEXdose SELECT Delivery Program Delivery program offering 3mL vial configuration with reduced microsphere volume (approximately 27 million microspheres versus 44 million in standard 5mL vials) for tailored, patient-specific Y-90 dosing and more selective treatment targeting, with flexible pre-calibration options.

Quantifiable outcome

• 90% complete response rate, 99% overall response rate, and 100% local tumor control at 12 months in unresectable HCC (DOORwaY90 trial)
• +6 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• MIM Software Inc.coreTechnology or Integration · 12 February 2020Sirtex entered a collaboration with MIM Software Inc., a leading global provider of imaging solutions in radiation oncology, radiology, nuclear medicine, neuroimaging, and cardiac imaging. Under the agreement, Sirtex's specialized sales teams in the U.S., Europe, and other key global markets offer MIM SurePlan LiverY90 software alongside SIR-Spheres Y-90 resin microspheres to improve treatment precision for hepatic tumors. The software provides dosimetry calculation tools and post-treatment analysis incorporating CT, PET, SPECT, and MRI scans.
• OncoSec Medical IncorporatedcoreStrategic or Co-development Partner · 10 October 2019Sirtex invested $30M alongside CGP in OncoSec (Nasdaq: ONCS), a late-stage intratumoral cancer immunotherapy company developing TAVO (tavokinogene telseplasmid) and Visceral Lesion Applicator (VLA). Sirtex acquired ~8.8% of OncoSec shares and supports pre-marketing activities for TAVO and VLA in exchange for low single-digit royalties outside the Greater China and Asian territory licensed to CGP. The transaction closed February 10, 2020.
• NHS EnglandminorOthers · 1 April 2019NHS England announced routine commissioning of selective internal radiation therapy (SIRT) using yttrium-90 microspheres for NHS patients with advanced colorectal cancer that has spread to the liver and is not responding to standard chemotherapies, effective April 2019.
• Cancer Research UK / University of OxfordminorStrategic or Co-development Partner · 6 October 2016The FOXFIRE study is an investigator-initiated study funded by the Bobby Moore Fund of Cancer Research UK and sponsored by the University of Oxford, with Sirtex providing support. This collaboration generated clinical evidence for SIR-Spheres in metastatic colorectal cancer.
• Discovery HealthminorOthers · 12 May 2016Discovery Health, the leading South African private health insurer, agreed to reimburse SIR-Spheres Y-90 resin microspheres for the treatment of all forms of inoperable liver tumours. This reimbursement approval provided improved patient access to SIRT therapy for South African patients.

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Siemens Healthineers: Siemens Healthineers, through Varian, is a leading radiation oncology and interventional imaging vendor whose hardware and software ecosystems intersect with SIRT treatment planning and post-treatment imaging for liver-directed therapies.
• Terumo: Terumo is a global interventional access and oncology device incumbent supplying microcatheters, guidewires, and embolic products used by the same interventional radiologists who administer SIR-Spheres, making it an adjacent competitor in the liver-directed therapy workflow.
• GE HealthCare: GE HealthCare supplies imaging, interventional radiology, and nuclear medicine equipment (CT, PET, SPECT, MRI) that is integral to SIRT planning and dosimetry, and overlaps with Sirtex at the hospital system level across interventional oncology service lines.
• Guerbet: Guerbet is a France-based specialist in diagnostic and interventional imaging, including Lipiodol and other embolization products for HCC, competing in the same interventional oncology procedures where SIR-Spheres is administered.
• Curium: Curium is one of the largest nuclear medicine and radiopharmaceutical manufacturers globally, supplying diagnostic and therapeutic isotopes and competing with Sirtex in the broader radiopharmaceutical value chain relevant to liver cancer imaging and therapy.
• Philips: Philips is a major vendor of interventional imaging and image-guided therapy systems used in SIRT workflows and competes broadly with Sirtex-relevant modalities (interventional X-ray, ultrasound, image fusion).

Direct peers

• Boston Scientific: Boston Scientific markets TheraSphere Y-90 glass microspheres, the most direct competitor to SIR-Spheres in Y-90 radioembolization for liver cancer, and acquired BTG to expand this franchise. Both companies compete for the same interventional radiologist call point across HCC and mCRC.

Emerging players

• Telix Pharmaceuticals: Telix is an emerging radiopharmaceutical company developing diagnostic and therapeutic agents for oncology, with a growing pipeline in liver and prostate cancer that competes for the same nuclear medicine physician customer and same hospital budgets as SIR-Spheres.
• Eckert & Ziegler: Eckert & Ziegler is a specialist in isotope technology and radiopharmaceutical services, supplying radiochemical components and contract manufacturing for therapeutic and diagnostic isotopes that overlap with Sirtex's Y-90 supply chain.

Others

• Sirtex Medical (parent context: China Grand Pharmaceutical): China Grand Pharmaceutical and Healthcare Holdings is Sirtex's majority owner and a Hong Kong-listed healthcare conglomerate that itself distributes oncology and nuclear medicine products across Greater China, making it both parent and a channel-aligned comparator in interventional oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SirtexMedical
• YouTubeyoutube.com/user/SirtexMedicalUS
• LinkedInlinkedin.com/company/sirtex-medical-limited

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sirtex Medical